MedTrace Logo

Addition of Radiotherapy to Standard Medical Treatment for Stage IV NSCLC

NCT04530708 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 162

Last updated 2020-08-28

No results posted yet for this study

Summary

The hypothesis for this study is that addition of a moderate dose of radiotherapy to the primary tumor and mediastinal nodes after three months of medical treatment could reduce the tumor burden, partly as an abscopal effect, and thereby improving quality of life and possible also prolonging survival for stage IV NSCLC.

Conditions

  • Radiotherapy
  • Non Small Cell Lung Cancer
  • Stage IV Non-small Cell Lung Cancer
  • Quality of Life

Interventions

RADIATION

Thoracic radiotherapy

36 Gy to the primary lung tumor and present mediastinal node metastases after three months of medical treatment.

Sponsors & Collaborators

  • Swedish Lung Cancer Study Group

    lead NETWORK

Principal Investigators

  • Jan Nyman, Ass.prof · Sahlgrenska University Hospital

  • Thomas Björk-Eriksson, Prof. · Regionalt Cancercentrum Väst

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-01
Primary Completion
2024-02-01
Completion
2026-02-01

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04530708 on ClinicalTrials.gov